高盛上调Agios(AGIO.US)目标价至28美元，看好地中海贫血新药Aqvesme上市前景

智通财经2025-12-26

智通财经APP获悉，高盛把Agios Pharmaceuticals(AGIO.US)的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme(mitapivat)获FDA批准后的市场前景与风险评估。Agios Pharmaceuticals作为专注创新疗法的生物制药公司，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594955102?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-26 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594955102","market":"fut","top_or_hot":-1,"title":"高盛上调Agios(AGIO.US)目标价至28美元，看好地中海贫血新药Aqvesme上市前景","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，高盛把Agios Pharmaceuticals(AGIO.US)的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme(mitapivat)获FDA批准后的市场前景与风险评估。Agios Pharmaceuticals作为专注创新疗法的生物制药公司，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386085.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛上调Agios(AGIO.US)目标价至28美元，看好地中海贫血新药Aqvesme上市前景</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛上调Agios(AGIO.US)目标价至28美元，看好地中海贫血新药Aqvesme上市前景\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-26 19:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1386085.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，高盛把Agios Pharmaceuticals(AGIO.US)的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme(mitapivat)获FDA批准后的市场前景与风险评估。Agios Pharmaceuticals作为专注创新疗法的生物制药公司，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386085.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1386085.html","article_id":"2594955102","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594955102","pubTimestamp":1766747977,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，高盛把Agios Pharmaceuticals的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme获FDA批准后的市场前景与风险评估。ENERGIZE-T方面，Aqvesme组10%的病人在48周内摆脱输血，安慰剂组只有1%，输血负荷下降幅度同样显著。综合来看，高盛认为Agios短期靠Aqvesme美国上市兑现第一波价值，中期看处方-收入错配何时收敛，长期则取决于镰状细胞病适应症能否再下一城。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Goldman Sachs raises the target price of Agios (AGIO.US) to $28, optimistic about the launch prospects of new thalassemia drug Aqvesme","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1.5},"content_text":"智通财经APP获悉，高盛把Agios Pharmaceuticals(AGIO.US)的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme(mitapivat)获FDA批准后的市场前景与风险评估。Agios Pharmaceuticals作为专注创新疗法的生物制药公司，Aqvesme成为首个且唯一获批治疗成人输血依赖型(TD)和非输血依赖型(NTD)α-或β-地中海贫血贫血的药物，该批准基于Ph3 ENERGIZE-T和ENERGIZE试验的显著疗效数据——在非输血依赖型患者中，42.3%的Aqvesme治疗组患者血红蛋白浓度显著提升，而安慰剂组仅1.6%;输血依赖型患者中，10%在48周内实现输血独立，安慰剂组仅1%。具体来说，FDA的批准基于两项Ⅲ期注册临床：ENERGIZE(NTD)与ENERGIZE-T(TD)。在ENERGIZE试验里，194名受试者中42.3%的Aqvesme组患者达到血红蛋白≥1 g/dL的主要终点，而安慰剂仅1.6%(p<0.0001);疲劳评分、平均血红蛋白浓度等次要指标也一并达标。ENERGIZE-T方面，Aqvesme组10%的病人在48周内摆脱输血，安慰剂组只有1%，输血负荷下降幅度同样显著。正因为数据扎实，高盛把Aqvesme在地中海贫血的上市概率从90%直接调到100%，并同步把模型中的美国年定价定在42.5万美元，比公司已上市同分子(Pyrukynd，用于丙酮酸激酶缺乏症)的33.5万美元再高出一截。然而疗效之外，肝损伤信号让监管不敢松懈。Ⅲ期里5例Aqvesme患者出现疑似肝细胞损伤，其中2例住院，所有事件发生在用药头六个月内，停药后肝指标恢复。FDA因此要求启动REMS项目：用药前必须查肝功，前24周每四周复测，此后按临床指征追踪;患者、处方医生与药房均需完成认证培训。Agios预计2026年1月底正式铺货，比无REMS的Pyrukynd晚一步，但公司认为程序性障碍不会显著拖慢渗透。市场究竟多大?管理层先锁定约4000名“最容易”的病人：TD人群2000人，外加症状明显、血红蛋白低或疲劳突出的NTD患者2000人。长期看，美国总可及人群约6000人，其中NTD占三分之二，与TD呈“倒三七”结构。高盛据此模型，预测2026财年Aqvesme销售额6900万美元(Visible Alpha共识3800万美元)，并认为2027年起处方与收入将同步爬坡，2033年达到全球峰值约6亿美元，与华尔街一致预期5.88亿美元几乎重合。值得注意的是，公司透露最初几个季度会呈现“处方走在收入前面”的特点：从填写启动表格到真正给药有10-12周滞后期，因此2026年底或2027年初才能看到两条曲线重合。现金流层面，高盛把2025-2027年收入预测依次调成3650万、4700万、1.46亿美元，同时维持亏损收窄节奏，预计2027年每股亏损6.25美元，比旧模型少亏约1美元。估值采用100%风险调整后DCF，WACC 17%、永续增长率3%，得出28美元目标价。若把管线溢价也算进去，高盛给出的情景里已包含Pyrukynd在丙酮酸激酶缺乏症100%成功、在镰状细胞病70%成功，以及Aqvesme在地中海贫血100%成功;换言之，28美元已经把“看得见”的商业化资产折现得满满当当。风险与向上弹性空间同样清晰。向上催化剂包括：后续镰状细胞病标签扩展顺利、竞争对手临床 setbacks 带来份额再分配、上市节奏与患者渗透快于预期;向下风险则涵盖管线读数不佳、肝毒性升级、竞品抢先、支付方施压降价、知识产权或生产瓶颈。高盛特意提醒，公司仍处在净亏损状态，若商业化速度低于预期，融资需求可能卷土重来。综合来看，高盛认为Agios短期靠Aqvesme美国上市兑现第一波价值，中期看处方-收入错配何时收敛，长期则取决于镰状细胞病适应症能否再下一城。28美元目标价对应2027年收入预测市销率约十倍，估值不算便宜，但放在罕见病“单品重磅”叙事里也算合理。投资者需要紧盯的，是明年一季度启动的处方曲线与肝安全信号，只要两者不出现方向性背离，Agios的小盘生物科技股性就会继续吸引事件驱动型资金。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594955102","isCrawlerRequest":true}